AHA Again Urges HHS to Protect 340B Program From Drug Companies’ Actions

September 8, 2020

AHA to HHS again expressing concern with recent actions taken by several major drug manufacturers to limit the distribution of certain 340B drugs to our hospital members. While we understand that the Health Resources and Services Administration (HRSA) is further investigating these actions, we urge swift and decisive action to halt these pernicious tactics so as to prevent other manufacturers from following suit.

Related Resources

Webinar Recordings
Member
Your browser does not support the video tag.
Special Bulletin
Public
President Trump yesterday signed an additional executive order aimed at lowering the price of prescription drugs. Three executive orders were signed in July…
Guides/Reports
Public
In 2017 alone, 340B Tax-exempt Hospitals Provided More Than $64 Billion in Total Benefits to Their Communities   Improving the health of their…
Action Alert
Member
In response to recent actions taken by a number of drug companies to limit the distribution of certain 340B drugs to hospitals and health systems, Reps. Diana…
Letter/Comment
Public
On behalf of the nation’s 340B hospitals, AHA, others urge the Department of Health and Human Services (HHS) to protect vulnerable communities from actions…
Letter/Comment
Public
AHA expresses profound concern about actions Eli Lilly and Company is taking to collect data intended to limit the distribution of certain 340B drugs to…